Overexpression of adenosine deaminase acting on RNA 1 in chordoma tissues is associated with chordoma pathogenesis by reducing miR‑125a and miR‑10a expression

Kuang,Lei; Lv,Guohua; Wang,Bing; Li,Lei; Dai,Yuliang; Li,Yawei

doi:10.3892/mmr.2015.3341

Overexpression of adenosine deaminase acting on RNA 1 in chordoma tissues is associated with chordoma pathogenesis by reducing miR‑125a and miR‑10a expression

Authors:
- Lei Kuang
- Guohua Lv
- Bing Wang
- Lei Li
- Yuliang Dai
- Yawei Li
View Affiliations

Affiliations: Department of Spinal Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China
Published online on: February 12, 2015 https://doi.org/10.3892/mmr.2015.3341
Pages: 93-98
Copyright: © Kuang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chordoma is a rare, slow‑growing primary malignant neoplasm of the axial skeleton, which arises from the remnants of the notochord. Emerging evidence suggests that microRNAs (miRs) are dysregulated in chordoma tissues and crucially involved in chordoma pathogenesis. In the present study, the expression of 11 candidate miRs were analyzed in chordoma tissues and miR‑10a and miR‑125a were found to be significantly downregulated compared with controls. Notably, the expression of the primary transcripts, pri‑miR‑125a and pri‑miR‑10a was unaltered, suggesting that disturbed microRNA expression may be induced by altered pri‑miRNA processing. Previous studies have indicated that disturbed adenosine deaminase acting on RNA (ADAR) expression is able to alter mRNA and miRNA adenosine to inosine (A‑to‑I) levels associated with cancer pathogenesis. Therefore, the expression of ADAR1 and ADAR2 was analyzed in chordoma tissues. It was found that ADAR1 was significantly overexpressed, which was accompanied by enhanced pre‑miR‑10a and pri‑miR‑125a A‑to‑I editing. These findings suggest that ADAR2 overexpression causes enhanced pre‑miR‑10a and pri‑miR‑125a A‑to‑I editing, which alters mature miR‑10a and miR‑125a expression and may contribute to chordoma pathogenesis.

View Figures

View References

1	Bydon M, Papadimitriou K, Witham T, et al: Novel therapeutic targets in chordoma. Expert Opin Ther Targets. 16:1139–1143. 2012. View Article : Google Scholar : PubMed/NCBI
2	Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT and Ferreira MJ: Chordoma: current concepts, management and future directions. Lancet Oncol. 13:e69–e76. 2012. View Article : Google Scholar : PubMed/NCBI
3	DeLaney TF, Duan Z and Hornicek FJ: Proteomic profiling of chordoma. J Surg Oncol. 102:7192010. View Article : Google Scholar : PubMed/NCBI
4	Diaz RJ and Cusimano MD: The biological basis for modern treatment of chordoma. J Neurooncol. 104:411–422. 2011. View Article : Google Scholar : PubMed/NCBI
5	Yang C, Schwab JH, Schoenfeld AJ, et al: A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther. 8:2597–2605. 2009. View Article : Google Scholar : PubMed/NCBI
6	Wu WK, Lee CW, Cho CH, et al: MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene. 29:5761–5771. 2010. View Article : Google Scholar : PubMed/NCBI
7	Nicoloso MS, Spizzo R, Shimizu M, Rossi S and Calin GA: MicroRNAs - the micro steering wheel of tumour metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
8	Duan Z, Shen J, Yang X, et al: Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma. J Orthop Res. 32:695–701. 2014. View Article : Google Scholar : PubMed/NCBI
9	Bayrak OF, Gulluoglu S, Aydemir E, et al: MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. J Neurooncol. 115:143–151. 2013. View Article : Google Scholar : PubMed/NCBI
10	Duan Z, Choy E, Nielsen GP, et al: Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. J Orthop Res. 28:746–752. 2010.
11	Mo F, Wyatt AW, Sun Y, et al: Systematic identification and characterization of RNA editing in prostate tumors. PloS One. 9:e1014312014. View Article : Google Scholar : PubMed/NCBI
12	Valles I, Pajares MJ, Segura V, et al: Identification of novel deregulated RNA metabolism-related genes in non-small cell lung cancer. PloS One. 7:e420862012. View Article : Google Scholar : PubMed/NCBI
13	Chan TH, Lin CH, Qi L, et al: A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 63:832–843. 2014. View Article : Google Scholar :
14	Maas S, Patt S, Schrey M and Rich A: Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci USA. 98:14687–14692. 2001. View Article : Google Scholar : PubMed/NCBI
15	Choudhury Y, Tay FC, Lam DH, et al: Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. J Clin Invest. 122:4059–4076. 2012. View Article : Google Scholar : PubMed/NCBI
16	Liu WH, Chen CH, Yeh KH, et al: ADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancers. PloS One. 8:e819222013. View Article : Google Scholar
17	Yang W, Chendrimada TP, Wang Q, et al: Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol. 13:13–21. 2006. View Article : Google Scholar
18	Kawahara Y, Zinshteyn B, Sethupathy P, Iizasa H, Hatzigeorgiou AG and Nishikura K: Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science. 315:1137–1140. 2007. View Article : Google Scholar : PubMed/NCBI
19	Berindan-Neagoe I and Calin GA: Molecular Pathways: microRNAs, cancer cells, and microenvironment. Clin Cancer Res. 20:6247–6253. 2014. View Article : Google Scholar : PubMed/NCBI
20	Zhang Y, Schiff D, Park D and Abounader R: MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. PloS One. 9:e915462014. View Article : Google Scholar : PubMed/NCBI
21	Fortunato O, Boeri M, Moro M, et al: Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. Cell Death Dis. 5:e15642014. View Article : Google Scholar : PubMed/NCBI
22	Finlay-Schultz J, Cittelly DM, Hendricks P, et al: Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. Sep 22–2014.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
23	Jia H, Zhang Z, Zou D, et al: MicroRNA-10a is down-regulated by DNA methylation and functions as a tumor suppressor in gastric cancer cells. PLoS one. 9:e880572014. View Article : Google Scholar : PubMed/NCBI
24	Hudson J, Duncavage E, Tamburrino A, et al: Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. Exp Mol Pathol. 95:62–67. 2013. View Article : Google Scholar : PubMed/NCBI
25	Markou A, Sourvinou I, Vorkas PA, Yousef GM and Lianidou E: Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 81:388–396. 2013. View Article : Google Scholar : PubMed/NCBI
26	Jiang L, Huang Q, Chang J, Wang E and Qiu X: MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp Lung Res. 37:387–398. 2011. View Article : Google Scholar : PubMed/NCBI
27	Guo X, Wu Y and Hartley RS: MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol. 6:575–583. 2009. View Article : Google Scholar : PubMed/NCBI
28	Hoppe R, Achinger-Kawecka J, Winter S, et al: Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. Eur J Cancer. 49:3598–3608. 2013. View Article : Google Scholar : PubMed/NCBI